GLP-3 RTA vs BPC-157 + TB-500
GLP-3 RTA and BPC-157 + TB-500 come from different research areas and are studied in largely separate models — researchers usually compare them when scoping a broader protocol.
✓ both US-made · third-party tested · batch COA on every order
Last updated August 25, 2026
How do GLP-3 RTA and BPC-157 + TB-500 differ?
GLP-3 RTA (Synthetic triple-agonist peptide) is catalogued under weight & metabolic research; BPC-157 + TB-500 (Co-formulated two-peptide research blend) is catalogued under recovery & gut research. Verve lists 5 reported research applications for GLP-3 RTA and 5 for BPC-157 + TB-500. Both are made in the United States, screened by HPLC to a 99%+ purity standard, and shipped with a batch-level certificate of analysis.
| field | GLP-3 RTA | BPC-157 + TB-500 |
|---|---|---|
| compound class | Synthetic triple-agonist peptide | Co-formulated two-peptide research blend |
| research area | weight & metabolic | recovery & gut |
| reported research applications | 5 listed | 5 listed |
| supplied as | single compound | co-formulated blend |
| catalog sizes | 10mg · 20mg · 30mg | 20mg |
| purity standard | 99%+ by HPLC | 99%+ by HPLC |
| manufactured | United States | United States |
| batch COA | published per lot | published per lot |
| endotoxin-tested option | available | available |
| co-formulated together in | not co-formulated | not co-formulated |
| price from | $142.99 | $171.49 |
| availability | in stock | in stock |
Prices and stock read live from the catalog. Both compounds are supplied strictly as reference materials for in-vitro laboratory research.
What is GLP-3 RTA and what is BPC-157 + TB-500?
GLP-3 RTA is classified as Synthetic triple-agonist peptide; BPC-157 + TB-500 as Co-formulated two-peptide research blend. Both profiles below cover scientific identity only — what the molecule is and which laboratory models it appears in. Verve supplies both strictly as in-vitro reference materials, and neither profile describes human or veterinary use.
GLP-3 RTA
Synthetic triple-agonist peptide
GLP-3 RTA is a synthetic single-chain peptide engineered to act at three related class B G-protein-coupled receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its backbone is derived from the incretin peptide family and carries a fatty-acid modification that extends plasma half-life in pre-clinical systems, making it a widely cited reference agonist in incretin-receptor research.
full GLP-3 RTA profile →BPC-157 + TB-500
Co-formulated two-peptide research blend
BPC-157 + TB-500 is a co-formulated research blend that combines two of the most frequently cited reference peptides in tissue-repair literature, BPC-157 / TB-500, in a single vial. BPC-157 is a synthetic pentadecapeptide derived from a partial sequence identified in human gastric juice; TB-500 is a synthetic 43-amino-acid peptide corresponding to an active fragment of thymosin beta-4, a naturally-occurring actin-binding protein.
full BPC-157 + TB-500 profile →Which research models is each compound studied in?
GLP-3 RTA sits in weight & metabolic research and BPC-157 + TB-500 in recovery & gut research, so their listed models largely do not intersect. The table lists 5 reported research applications for GLP-3 RTA and 5 for BPC-157 + TB-500. Rows are per compound, not equivalences.
| GLP-3 RTA — reported research applications | BPC-157 + TB-500 — reported research applications |
|---|---|
| GLP-1, GIP, and glucagon receptor agonism research | Multi-compound tissue-repair research models |
| cAMP and class B GPCR signaling research models | Cell-migration and wound-healing research |
| Comparative single-, dual-, and triple-agonist pharmacology studies | Angiogenesis and vascular-signaling research |
| Metabolic-pathway and nutrient-handling research models | Actin-regulation and cytoskeletal research |
| Peptide half-life, lipidation, and stability research | Comparative research on blended versus single-peptide preparations |
Research contexts only. Both compounds are supplied for laboratory research use only, and no entry above describes an effect in humans or animals.
What sizes and prices does verve list for GLP-3 RTA and BPC-157 + TB-500?
GLP-3 RTA is listed from $142.99 and BPC-157 + TB-500 from $171.49. The table below is every catalog size verve currently lists for the two compounds, at single-vial prices before the automatic multi-compound discount. Sizes describe the vial format supplied to the laboratory, nothing more.
| compound | size listed | price | availability |
|---|---|---|---|
| GLP-3 RTA | 10mg | $142.99 | in stock |
| GLP-3 RTA | 20mg | $242.99 | in stock |
| GLP-3 RTA | 30mg | $328.99 | in stock |
| BPC-157 + TB-500 | 20mg | $171.49 | in stock |
Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.
shop the compounds →Frequently asked questions about GLP-3 RTA and BPC-157 + TB-500
What is GLP-3 RTA?
GLP-3 RTA is a synthetic peptide that acts as an agonist at three receptors — GLP-1, GIP, and glucagon. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is GLP-3 RTA studied for in research?
In in-vitro and pre-clinical models it is used as a reference agonist in incretin-receptor pharmacology, cAMP signaling, and metabolic-pathway research. Verve makes no claims about use in humans or animals.
What is BPC-157 + TB-500?
BPC-157 + TB-500 is a co-formulated research blend of two well-characterized reference peptides, BPC-157 / TB-500, supplied in one vial. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is the BPC-157 / TB-500 blend studied for in research?
It is used in multi-compound cellular models covering tissue repair, cell migration, angiogenesis, and actin regulation, where both peptides are studied together. Verve makes no health claims.
related comparisons
verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.